<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2025.1482112</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Understanding cellular proliferation activity in breast cancer using multi-compartment model of transverse relaxation time mapping on 3T MRI</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nkonde</surname>
<given-names>Kangwa Alex</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2818476"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheung</surname>
<given-names>Sai Man</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1366054"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Senn</surname>
<given-names>Nicholas</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2806239"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>He</surname>
<given-names>Jiabao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1259852"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University</institution>, <addr-line>Newcastle upon Tyne</addr-line>, <country>United Kingdom</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Physics, School of Natural and Applied Sciences, Mulungushi University</institution>, <addr-line>Kabwe</addr-line>, <country>Zambia</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen</institution>, <addr-line>Aberdeen</addr-line>, <country>United Kingdom</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Michael Albert Thomas, University of California, Los Angeles, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Glaucia Maria Machado-Santelli, University of S&#xe3;o Paulo, Brazil</p>
<p>Yen-Peng Liao, University of Texas Southwestern Medical Center, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Jiabao He, <email xlink:href="mailto:jiabao.he@newcastle.ac.uk">jiabao.he@newcastle.ac.uk</email>
</p>
</fn>
<fn fn-type="other" id="fn003">
<p>&#x2020;These authors share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>01</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>15</volume>
<elocation-id>1482112</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>08</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>01</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Nkonde, Cheung, Senn and He</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Nkonde, Cheung, Senn and He</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Precise understanding of proliferative activity in breast cancer holds significant value in the monitoring of neoadjuvant treatment, while current immunostaining of Ki-67 from biopsy or resected tumour suffers from partial sampling error. Multi-compartment model of transverse relaxation time has been proposed to differentiate intra- and extra-cellular space and biochemical environment but susceptible to noise, with recent development of Bayesian algorithm suggested to improve robustness. We hence hypothesise that intra- and extra-cellular transverse relaxation times using Bayesian algorithm might be sensitive to proliferative activity.</p>
</sec>
<sec>
<title>Materials and methods</title>
<p>Twenty whole tumour specimens freshly excised from patients with invasive ductal carcinoma were scanned on a 3 T clinical scanner. The overall transverse relaxation time was computed using a single-compartment model with the non-linear least squares algorithm, while intra- and extra-cellular transverse relaxation times were computed using a multi-compartment model with the Bayesian algorithm. Immunostaining of Ki-67 was conducted, yielding 9 and 11 cases with high and low proliferating activities respectively.</p>
</sec>
<sec>
<title>Results</title>
<p>For single-compartment model, there was a significant higher overall transverse relaxation time (<italic>p</italic> = 0.031) in high (83.55 &#xb1; 7.38 ms) against low (73.30 &#xb1; 11.30 ms) proliferating tumours. For multi-compartment model, there was a significant higher intra-cellular transverse relaxation time (<italic>p</italic> = 0.047) in high (73.52 &#xb1; 10.92 ms) against low (61.30 &#xb1; 14.01 ms) proliferating tumours. There was no significant difference in extra-cellular transverse relaxation time (<italic>p</italic> = 0.203) between high and low proliferating tumours.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Overall and Bayesian intra-cellular transverse relaxation times are associated with proliferative activities in breast tumours, potentially serving as a non-invasive imaging marker for neoadjuvant treatment monitoring.</p>
</sec>
</abstract>
<kwd-group>
<kwd>neoadjuvant treatment</kwd>
<kwd>Bayesian</kwd>
<kwd>Ki-67</kwd>
<kwd>intra-cellular</kwd>
<kwd>extra-cellular</kwd>
<kwd>biochemical environment</kwd>
</kwd-group>
<contract-sponsor id="cn001">Newcastle University<named-content content-type="fundref-id">10.13039/501100000774</named-content>
</contract-sponsor>
<counts>
<fig-count count="5"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="59"/>
<page-count count="11"/>
<word-count count="3728"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Imaging and Image-directed Interventions</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>New pharmaceutical options and the improvement in screening services have improved the 5-year survival rate of breast cancer (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>), the most prevalent cancer worldwide (<xref ref-type="bibr" rid="B3">3</xref>), from 79.9% between 2000 &#x2013; 2004 to 86.3% between 2014 &#x2013; 2018 in the UK. Neoadjuvant therapies, often a combination of chemotherapy and hormonal therapy, are increasingly used to improve surgical outcomes by downstaging large tumours to facilitate breast conservation surgery (<xref ref-type="bibr" rid="B4">4</xref>). Neoadjuvant therapy is typically lengthy and costly, exposing non-responding patients to unnecessary potential adverse effects (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Rapid tumour growth, a central prognostic indicator of breast cancer, can be estimated using the proliferative activity marker Ki-67, highlighting nuclear protein expressed during cell division (<xref ref-type="bibr" rid="B7">7</xref>). However, Ki-67 using biopsy is invasive with narrow spatial coverage, suboptimal for accurately estimating intrinsically heterogeneous proliferative activity across the whole tumour during treatment (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). Hence, an imaging marker of proliferative activity is central to effective neoadjuvant treatment monitoring in breast cancer.</p>
<p>PET tracer of 3&#x2019;-deoxy-3&#x2019;-[18F] fluorothymidine (FLT) has been shown to correlate with Ki-67 in breast cancer (<xref ref-type="bibr" rid="B10">10</xref>), but causes myelosuppression, peripheral neuropathy and nausea at high doses (<xref ref-type="bibr" rid="B7">7</xref>). Peri-tumoural texture features of kurtosis, skewness and entropy, based on maximum enhancement from dynamic contrast-enhanced (DCE) MRI are associated with proliferative activity in large cohorts (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>), but the primary sensitivity of DCE MRI towards angiogenesis compromises specificity (<xref ref-type="bibr" rid="B13">13</xref>). Apparent diffusion coefficient from diffusion weighted imaging (DWI) can distinguish between low and high proliferating breast tumours (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B14">14</xref>), but is susceptible to biological noise (<xref ref-type="bibr" rid="B15">15</xref>). Both peri-tumoural lipid composition from chemical shift-encoded imaging (CSEI) (<xref ref-type="bibr" rid="B16">16</xref>) and perfusion fraction from intravoxel incoherent motion (IVIM) MRI (<xref ref-type="bibr" rid="B17">17</xref>) have shown correlations against proliferative activity, but the primary sensitivity to tissue composition and perfusion limits specificity (<xref ref-type="bibr" rid="B18">18</xref>). Hence, an imaging approach specific to proliferative activity with low susceptibility to biological noise is highly desirable.</p>
<p>Transverse relaxation time mapping has been shown to highlight tumour pathology (<xref ref-type="bibr" rid="B19">19</xref>), but only offers a crude picture of tissue microenvironment (<xref ref-type="bibr" rid="B20">20</xref>). Rapidly proliferating tumours are associated with elevated angiogenesis to support accelerated metabolic activities (<xref ref-type="bibr" rid="B21">21</xref>) exacerbating vascular permeability and fluid efflux (<xref ref-type="bibr" rid="B22">22</xref>), and the consequent increased free water pool and a diluted biochemical microenvironment (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B23">23</xref>) lead to elevated transverse relaxation time in high proliferating breast tumours as observed <italic>in vivo</italic> (<xref ref-type="bibr" rid="B24">24</xref>). Intra-cellular transverse relaxation time, although more susceptible to noise compared to overall transverse relaxation time, is more specific to alterations in intra-cellular processes (<xref ref-type="bibr" rid="B25">25</xref>), potentially revealing tumour response to chemotherapy targeting at rapid cell division at an early stage (<xref ref-type="bibr" rid="B26">26</xref>). Recent application of multi-compartment model differentiates lumen, intra- and extra-cellular spaces, as demonstrated in luminal water imaging in prostate cancer (<xref ref-type="bibr" rid="B27">27</xref>), classification of adipocytic tumour in soft tissue (<xref ref-type="bibr" rid="B28">28</xref>), differentiation of layers in articular cartilage (<xref ref-type="bibr" rid="B29">29</xref>) and estimation of myelin volume in the brain (<xref ref-type="bibr" rid="B30">30</xref>). Although multi-compartment model has been suggested as a marker of proliferative activity in breast cancer (<xref ref-type="bibr" rid="B31">31</xref>), the susceptibility to erroneous attribution of noise (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B29">29</xref>) significantly curtailed the clinical application. Bayesian algorithm, using probabilistic constraints between neighbouring image voxels, was subsequently developed to reduce susceptibility to noise (<xref ref-type="bibr" rid="B32">32</xref>&#x2013;<xref ref-type="bibr" rid="B34">34</xref>), and we have recently demonstrated the value in improving imaging methods for neoadjuvant treatment monitoring (<xref ref-type="bibr" rid="B17">17</xref>). We hence hypothesise that multi-compartment model of transverse relaxation time mapping using Bayesian algorithm might be a sensitive marker of proliferative activity.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<p>To probe this hypothesis, a cross-sectional study was conducted on 20 breast tumour specimens freshly excised from patients. Multi-compartment model of transverse relaxation time maps using Bayesian algorithm was performed to derive the intra- and extra-cellular transverse relaxation times and the volume ratio of each breast tumour specimen (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). The study was approved by the North-West &#x2013; Greater Manchester East Research Ethics Committee (REC Reference: 16/NW/0221), and signed written informed consent was obtained from all participants prior to the study.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Study design. Twenty specimens freshly excised from patients with invasive ductal carcinoma grades II and III were imaged on a clinical 3T MRI scanner using quantitative transverse relaxation time mapping, with subsequent histopathological confirmation of low and high cellular proliferation activity. The overall transverse relaxation time was computed voxel-wise using a single-compartment model, while the intra- and extra-cellular transverse relaxation times and volume ratio were calculated voxel-wise using a multi-compartment model.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1482112-g001.tif"/>
</fig>
<sec id="s2_1">
<label>2.1</label>
<title>Clinical procedure</title>
<p>Fresh tumour specimens were excised from twenty female patients (age mean 57 years, range 35 to 78 years) with invasive ductal carcinoma (IDC) (10 grade II and 10 grade III). The study included patients with tumour size larger than 1.5 cm in diameter on mammography. Patients with previous malignancies and undergoing chemotherapy or radiotherapy prior to surgery were excluded from the study. Upon excision, the tumour specimens were immobilised in a 10% buffered formalin solution in a sealed container before imaging. Routine histopathological examination was performed to determine the histological tumour diameter, grade and Nottingham Prognostic Index (NPI), with oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) (<xref ref-type="bibr" rid="B35">35</xref>). Tumour cellular proliferation activity marker Ki-67 (<xref ref-type="bibr" rid="B36">36</xref>) was assessed semi-quantitatively after single-batch immunostaining, with high Ki-67 indicating that more than 14% (<xref ref-type="bibr" rid="B37">37</xref>) of tumour cell nuclei staining positive above the background (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>), and there were 9 and 11 cases with high and low proliferative activities respectively.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Transverse relaxation time mapping</title>
<p>Quantitative transverse relaxation time images were acquired from each specimen on a clinical 3T MRI scanner (Achieva TX, Philips Healthcare, Netherlands) using a 32-channel receiver coil for signal detection and the body coil for uniform transmission. The images were acquired using a multishot gradient and spin echo (GRASE) sequence (<xref ref-type="bibr" rid="B40">40</xref>), with 24 echoes, initial echo time of 13 ms, echo spacing of 13 ms, repetition time of 9943 ms, field of view of 141 &#xd7; 141 mm<sup>2</sup>, slice thickness of 2.2 mm, and image resolution of 2.2 &#xd7; 2.2 mm<sup>2</sup>. The overall transverse relaxation time was computed voxel-wise using single-compartment model with the non-linear least squares method in MATLAB (R2021a, MathWorks Inc., Natick, MA, USA). The intra- and extra-cellular transverse relaxation times and volume ratio were calculated voxel-wise using the multi-compartment model with the Bayesian algorithm (<xref ref-type="bibr" rid="B33">33</xref>). The whole tumour was delineated for each specimen using MRIcron (v1.0.20190902, University of South Carolina, Colombia, USA) on conventional DWI images acquired at <italic>b</italic> value at 800 smm<sup>-2</sup> using pulsed gradient spin echo (PGSE) sequence, with the necrotic regions excluded from the analysis. The overall transverse relaxation time, intra- and extra-cellular transverse relaxation times, and intra- and extra-cellular volumes were computed as the mean within the whole tumour from corresponding quantitative maps for each specimen, and the volume ratio subsequently calculated as the ratio between intra-cellular volume against combined intra- and extra-cellular volumes (<xref ref-type="bibr" rid="B27">27</xref>).</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Statistical analysis</title>
<p>All statistical analysis was performed in the SPSS software 27.0 (IBM Corp, Armonk, NY, USA). Shapiro-Wilk test for normality was performed on all the outcome measures. Independent sample <italic>t</italic>-tests or Mann-Whitney <italic>U</italic> tests were conducted to compare the overall, intra- and extra-cellular transverse relaxation times and volume ratio between tumours with high and low proliferative activities. Pearson&#x2019;s correlation tests were performed between the overall transverse relaxation time, intra-cellular transverse relaxation time and volume ratio against the tumour diameter, with Spearman&#x2019;s rank correlation test performed between the extra-cellular transverse relaxation time against the tumour diameter. Spearman&#x2019;s rank correlation tests were performed between the transverse relaxation times and volume ratio against NPI. A <italic>p</italic>-value &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<p>The patient demography and statistical findings are shown in <xref ref-type="table" rid="T1">
<bold>Tables&#xa0;1</bold>
</xref>, <xref ref-type="table" rid="T2">
<bold>2</bold>
</xref> respectively. There were no significant differences in patient characteristics between the high and low Ki-67 groups.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Patient demography.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="left">Demographic</th>
<th valign="middle" rowspan="2" align="left">All <break/>(n = 20)</th>
<th valign="middle" colspan="2" align="center">Ki-67 expression</th>
<th valign="middle" rowspan="2" align="left">
<italic>p-value</italic>
</th>
</tr>
<tr>
<th valign="middle" align="left">Low <break/>(n = 11)</th>
<th valign="middle" align="left">High <break/>(n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Age (years)<sup>^</sup>
</td>
<td valign="middle" align="left">58 &#xb1; 14</td>
<td valign="middle" align="left">63 &#xb1; 11</td>
<td valign="middle" align="left">51 &#xb1; 12</td>
<td valign="middle" align="left">0.052</td>
</tr>
<tr>
<td valign="middle" align="left">Tumour Size (mm)<sup>^</sup>
</td>
<td valign="middle" align="left">24.9 &#xb1; 5.7</td>
<td valign="middle" align="left">24.1 &#xb1; 6.6</td>
<td valign="middle" align="left">25.9 &#xb1; 4.7</td>
<td valign="middle" align="left">0.489</td>
</tr>
<tr>
<td valign="middle" align="left">Nottingham Prognostic Index (NPI) <sup>&#x2020;</sup>
</td>
<td valign="middle" align="left">4.44 (3.50 &#x2013; 4.59)</td>
<td valign="middle" align="left">3.70 (3.50 &#x2013; 4.57)</td>
<td valign="middle" align="left">4.44 (4.42 &#x2013; 4.60)</td>
<td valign="middle" align="left">0.199</td>
</tr>
<tr>
<th valign="middle" colspan="5" align="left">Histological grade<sup>*</sup>
</th>
</tr>
<tr>
<td valign="middle" align="left">II</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">2</td>
<td valign="middle" rowspan="2" align="left">0.070</td>
</tr>
<tr>
<td valign="middle" align="left">III</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">7</td>
</tr>
<tr>
<th valign="middle" colspan="5" align="left">Lymphovascular Invasion (LVI)<sup>*</sup>
</th>
</tr>
<tr>
<td valign="middle" align="left">LVI Positive</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">5</td>
<td valign="middle" rowspan="2" align="left">1</td>
</tr>
<tr>
<td valign="middle" align="left">LVI Negative</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">4</td>
</tr>
<tr>
<th valign="middle" colspan="5" align="left">Necrosis<sup>*</sup>
</th>
</tr>
<tr>
<td valign="middle" align="left">Present</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">3</td>
<td valign="middle" rowspan="2" align="left">0.406</td>
</tr>
<tr>
<td valign="middle" align="left">Absent</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">6</td>
</tr>
<tr>
<th valign="middle" colspan="5" align="left">Tumour Infiltrating Lymphocytes (TILs)<sup>*</sup>
</th>
</tr>
<tr>
<td valign="middle" align="left">Low</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">1</td>
</tr>
<tr>
<td valign="middle" align="left">Intermediate</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">0.591</td>
</tr>
<tr>
<td valign="middle" align="left">High</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">0.566</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<sup>^</sup>Independent samples <italic>t</italic>-test for continuous variables; <sup>&#x2020;</sup>Mann-Whitney <italic>U</italic>-test for continuous non-parametric variables; <sup>*</sup>Fisher's exact test for categorical variables.</p>
</fn>
<fn>
<p>Breast cancer patients with high and low proliferative activity marker Ki-67 expression are shown for each group and the entire cohort. Values are expressed as mean and standard deviation for normally distributed data, and median and interquartile range for non-normally distributed data. Histopathological entries are expressed as the number of positive observations.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Relaxometry properties in breast cancer.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="center">Parameter</th>
<th valign="middle" colspan="4" align="center">Molecular subtypes</th>
<th valign="middle" colspan="3" align="center">Ki-67 expression</th>
<th valign="middle" colspan="2" align="center">Tumour size</th>
<th valign="middle" colspan="2" align="center">NPI</th>
</tr>
<tr>
<th valign="middle" align="center">
<italic>Lum A</italic>
<break/>
<italic>(n = 9)</italic>
</th>
<th valign="middle" align="center">
<italic>Lum B-HER2 (</italic>&#x2013;)<break/>
<italic>(n = 4)</italic>
</th>
<th valign="middle" align="center">
<italic>Lum B-HER2(+)</italic>
<break/>
<italic>(n = 4)</italic>
</th>
<th valign="middle" align="center">
<italic>TN</italic>
<break/>
<italic>(n = 3)</italic>
</th>
<th valign="middle" align="center">
<italic>Low</italic>
<break/>
<italic>(n = 11)</italic>
</th>
<th valign="middle" align="center">
<italic>High</italic>
<break/>
<italic>(n = 9)</italic>
</th>
<th valign="middle" align="center">
<italic>p-value</italic>
</th>
<th valign="middle" align="center">
<italic>r/&#x3c1;</italic>
</th>
<th valign="middle" align="center">
<italic>p-value</italic>
</th>
<th valign="middle" align="center">
<italic>&#x3c1;</italic>
</th>
<th valign="middle" align="center">
<italic>p-value</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">
<italic>f</italic> (%)</td>
<td valign="middle" align="center">43.84 &#xb1; 9.86</td>
<td valign="middle" align="center">33.77 &#xb1; 5.68</td>
<td valign="middle" align="center">36.82 &#xb1; 10.87</td>
<td valign="middle" align="center">29.01 &#xb1; 7.17</td>
<td valign="middle" align="center">41.65 &#xb1; 10.08</td>
<td valign="middle" align="center">33.64 &#xb1; 8.33</td>
<td valign="middle" align="center">0.073</td>
<td valign="middle" align="center">0.02<sup>^</sup>
</td>
<td valign="middle" align="center">0.922</td>
<td valign="middle" align="center">-0.17<sup>+</sup>
</td>
<td valign="middle" align="center">0.473</td>
</tr>
<tr>
<td valign="middle" align="left">T<sub>2, MONO</sub> (ms)</td>
<td valign="middle" align="center">71.19 &#xb1; 11.45</td>
<td valign="middle" align="center">84.88 &#xb1; 8.41</td>
<td valign="middle" align="center">79.76 &#xb1; 5.71</td>
<td valign="middle" align="center">84.63 &#xb1; 4.54</td>
<td valign="middle" align="center">73.30 &#xb1; 11.30</td>
<td valign="middle" align="center">83.55 &#xb1; 7.38</td>
<td valign="middle" align="center">
<bold>0.031*</bold>
</td>
<td valign="middle" align="center">0.22<sup>^</sup>
</td>
<td valign="middle" align="center">0.360</td>
<td valign="middle" align="center">-0.06<sup>+</sup>
</td>
<td valign="middle" align="center">0.806</td>
</tr>
<tr>
<td valign="middle" align="left">T<sub>2L</sub> (ms)</td>
<td valign="middle" align="center">156.85 &#xb1; 21.08</td>
<td valign="middle" align="center">144.74 &#xb1; 9.05</td>
<td valign="middle" align="center">154.62 &#xb1; 5.98</td>
<td valign="middle" align="center">149.79 &#xb1; 11.23</td>
<td valign="middle" align="center">156.56 &#xb1; 19.16</td>
<td valign="middle" align="center">147.38 &#xb1; 8.84</td>
<td valign="middle" align="center">0.203</td>
<td valign="middle" align="center">-0.50<sup>+</sup>
</td>
<td valign="middle" align="center">
<bold>0.025*</bold>
</td>
<td valign="middle" align="center">0.02<sup>+</sup>
</td>
<td valign="middle" align="center">0.947</td>
</tr>
<tr>
<td valign="middle" align="left">T<sub>2S</sub> (ms)</td>
<td valign="middle" align="center">59.01 &#xb1; 14.56</td>
<td valign="middle" align="center">74.91 &#xb1; 11.35</td>
<td valign="middle" align="center">66.00 &#xb1; 4.66</td>
<td valign="middle" align="center">77.43 &#xb1; 9.58</td>
<td valign="middle" align="center">61.30 &#xb1; 14.01</td>
<td valign="middle" align="center">73.52 &#xb1; 10.92</td>
<td valign="middle" align="center">
<bold>0.047*</bold>
</td>
<td valign="middle" align="center">-0.01<sup>^</sup>
</td>
<td valign="middle" align="center">0.979</td>
<td valign="middle" align="center">-0.05<sup>+</sup>
</td>
<td valign="middle" align="center">0.828</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>HER2, Human epidermal growth factor receptor 2; Lum, Luminal; TN, Triple negative. <sup>^</sup>Pearson&#x2019;s correlation coefficient (<italic>r</italic>); <italic>
<sup>+</sup>
</italic>Spearman&#x2019;s rank correlation (<italic>&#x3c1;)</italic>.</p>
</fn>
<fn>
<p>The overall transverse relaxation time (T<sub>2, MONO</sub>), intra- and extra-cellular transverse relaxation times (T<sub>2S</sub>, T<sub>2L</sub>) and volume ratio (<italic>f</italic>) between molecular subtypes, and low and high Ki-67 expression are shown. The correlations of T<sub>2, MONO</sub>, T<sub>2S</sub>, T<sub>2L</sub> and <italic>f</italic> against tumour diameter and Nottingham Prognostic Index (NPI) are also shown. Statistically significant differences (p &lt; 0.05) are in bold and marked by '*'.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There was a significant higher overall transverse relaxation time (<italic>p</italic> = 0.031, <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>) in high Ki-67 tumours (83.55 &#xb1; 7.38 ms) against low Ki-67 tumours (73.30 &#xb1; 11.30 ms). There was a significant higher intra-cellular transverse relaxation time (<italic>p</italic> = 0.047, <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>) in high Ki-67 tumours (73.52 &#xb1; 10.92 ms) against low Ki-67 tumours (61.30 &#xb1; 14.01 ms). There was no significant difference (<italic>p</italic> = 0.203, <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>) in the extra-cellular transverse relaxation time between high Ki-67 tumours (147.38 &#xb1; 8.84 ms) and low Ki-67 tumours (156.56 &#xb1; 19.16 ms). There was no significant difference (<italic>p</italic> = 0.073, <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>) in volume ratio between high Ki-67 tumours (33.64 &#xb1; 8.33%) and low Ki-67 tumours (41.65 &#xb1; 10.08%).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Group comparison of relaxometry properties between low and high Ki-67 expression group in breast cancer (n = 11, 9). <bold>(A)</bold> Overall transverse relaxation times (T<sub>2, MONO</sub>) are significantly higher in high proliferating tumours than in low proliferating tumours, potentially indicating a diluted biochemical environment. <bold>(B)</bold> Intra-cellular transverse relaxation times (T<sub>2S</sub>) are significantly higher in high proliferating tumours than in low proliferating tumours, potentially indicating a dilution of the intra-cellular biochemical environment. <bold>(C)</bold> There was no significant difference in extra-cellular transverse relaxation times (T<sub>2L</sub>) between high and low proliferating tumours, suggesting biochemical homeostasis. <bold>(D)</bold> The near-significantly higher volume ratio (<italic>f</italic>), in low proliferating tumours than in high proliferating tumours, suggests possible physical homeostasis between intra- and extra-cellular fluid volumes. Each dot represents the mean ROI of the parameter, arranged by low (Ki-67 &#x2264; 14%) and high (Ki-67 &gt; 14%) proliferative activity. Error bars represent the mean &#xb1; standard deviation. Two-tailed independent <italic>t</italic>-tests were conducted, with <italic>p</italic>-values provided; statistically significant results (<italic>p</italic> &lt; 0.05) are marked by &#x2018;*&#x2019;.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1482112-g002.tif"/>
</fig>
<p>Against tumour diameter, there was a significant negative correlation in extra-cellular transverse relaxation time (<italic>&#x3c1; = -</italic>0.50<italic>, p =</italic> 0.025, <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>), but not in intra-cellular transverse relaxation time (<italic>p =</italic> 0.979), volume ratio (<italic>p =</italic> 0.922) and overall transverse relaxation time (<italic>p =</italic> 0.360) (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). There were no significant correlations between extra-cellular transverse relaxation time (<italic>p =</italic> 0.947), intra-cellular transverse relaxation time (<italic>p =</italic> 0.828), volume ratio (<italic>p =</italic> 0.473) and overall transverse relaxation time (<italic>p =</italic> 0.806) against NPI (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). Typical breast tumour specimens of high and low Ki-67 expression and the corresponding maps of overall and intra-cellular transverse relaxation times are shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>, and maps of extra-cellular transverse relaxation time and volume ratio are shown in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1</bold>
</xref> (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material 1</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Correlation analysis between relaxometry properties and breast tumour diameter (n = 20). <bold>(A)</bold> Extra-cellular transverse relaxation time (T<sub>2L</sub>). <bold>(B)</bold> Intra-cellular transverse relaxation time (T<sub>2S</sub>). <bold>(C)</bold> Volume ratio (<italic>f</italic>). <bold>(D)</bold> Overall transverse relaxation time (T<sub>2, MONO</sub>). Statistically significant correlations (<italic>p</italic> &lt; 0.05) are marked by &#x2018;*&#x2019;.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1482112-g003.tif"/>
</fig>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Correlation analysis between relaxometry properties and Nottingham Prognostic Index (NPI) in breast cancer (n = 20). <bold>(A)</bold> Extra-cellular transverse relaxation time (T<sub>2L</sub>). <bold>(B)</bold> Intra-cellular transverse relaxation time (T<sub>2S</sub>). <bold>(C)</bold> Volume ratio (<italic>f</italic>). <bold>(D)</bold> Overall transverse relaxation time (T<sub>2, MONO</sub>).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1482112-g004.tif"/>
</fig>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>High (Ki-67 &gt; 14%) and low (Ki-67 &#x2264; 14%) proliferating breast tumour specimens in haematoxylin and eosin (H &amp; E) staining and the corresponding transverse relaxation time maps. Sections are taken from the greatest dimension of the tumour diameter. Magnification, x20. <bold>(A)</bold> A high Ki-67 expression of 49.18%. <bold>(B)</bold> A low Ki-67 expression of 4.96%. <bold>(C)</bold> Overall transverse relaxation time (T<sub>2, MONO</sub>) map of the high Ki-67 specimen. <bold>(D)</bold> T<sub>2, MONO</sub> map of the low Ki-67 specimen. <bold>(E)</bold> Intra-cellular transverse relaxation time (T<sub>2S</sub>) map of the high Ki-67 specimen. <bold>(F)</bold> T<sub>2S</sub> map of the low Ki-67 specimen.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1482112-g005.tif"/>
</fig>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>In this study, we found significant differences between high and low proliferating tumours in overall and intra-cellular transverse relaxation times, but not in extra-cellular transverse relaxation time and volume ratio. We found a significant negative correlation of the extra-cellular transverse relaxation time against tumour diameter, but not in the remaining three relaxometry properties. No significant correlation of the four relaxometry properties against NPI was found.</p>
<p>The elevated overall transverse relaxation time in high proliferating tumours indicates a reduced rate of signal dissipation potentially due to a diluted biochemical environment (<xref ref-type="bibr" rid="B23">23</xref>). The rapid metabolic activity in high proliferating tumours results in increased free water pools in the tumour (<xref ref-type="bibr" rid="B21">21</xref>), while the enhanced angiogenesis exacerbates vascular permeability and fluid leakage into the tumour (<xref ref-type="bibr" rid="B22">22</xref>). Hence, the central characteristics of rapidly proliferating tumours (<xref ref-type="bibr" rid="B41">41</xref>), of increased metabolic activity and enhanced angiogenesis, contribute to the diluted biochemical environment in high proliferating tumours (<xref ref-type="bibr" rid="B42">42</xref>). The elevated intra-cellular transverse relaxation time in high proliferating tumours indicates a reduced rate of signal dissipation potentially due to a diluted intra-cellular biochemical environment (<xref ref-type="bibr" rid="B43">43</xref>). The rapid cell division in high proliferating tumours, as highlighted by Ki-67 (<xref ref-type="bibr" rid="B21">21</xref>), demands upregulated transportation of amino acids from the cytoplasmic space to sustain biosynthesis in the nucleus (<xref ref-type="bibr" rid="B44">44</xref>), leading to a diluted intra-cellular biochemical environment. The stronger statistical significance in overall transverse relaxation time compared to intra-cellular transverse relaxation time might be the result of lower intra-cellular signal as a fraction of the overall signal, but might also indicate the presence of feedforward and feedback pathways. Angiogenesis exacerbates vascular permeability to support accelerated metabolic activity, compounding fluid efflux in both the intra- and extra-cellular compartments (<xref ref-type="bibr" rid="B22">22</xref>), potentially leading to a more significant elevation in the overall transverse relaxation time in high proliferating tumours (<xref ref-type="bibr" rid="B23">23</xref>). In contrast, the elevated transportation of amino acids into the nucleus from the cytoplasmic space of the intra-cellular compartment to support accelerated biosynthesis in rapidly proliferating tumours partially cancels out the fluid efflux, potentially leading to a more subdued increase in the intra-cellular transverse relaxation time (<xref ref-type="bibr" rid="B44">44</xref>). Chemotherapies, targeting at rapid cell division, significantly alter the intra-cellular biochemical environment (<xref ref-type="bibr" rid="B26">26</xref>), hence sensitive imaging markers might contribute to early response monitoring (<xref ref-type="bibr" rid="B25">25</xref>). The lack of significant difference in the extra-cellular transverse relaxation time indicates an undisturbed rate of signal dissipation potentially reflecting biochemical homeostasis, although unnaturalised free radicals as by-products from aerobic glycolysis (<xref ref-type="bibr" rid="B45">45</xref>) are actively expelled to extra-cellular volume (<xref ref-type="bibr" rid="B46">46</xref>), promoting fibrosis (<xref ref-type="bibr" rid="B47">47</xref>), angiogenesis (<xref ref-type="bibr" rid="B22">22</xref>) and reduction of free water (<xref ref-type="bibr" rid="B48">48</xref>). The lack of significant difference in the volume ratio reflects the physical homeostasis of intra- and extra-cellular fluid volumes (<xref ref-type="bibr" rid="B49">49</xref>) critical for minimal disruption of osmotic pressure and transportation across cellular compartments in tumours (<xref ref-type="bibr" rid="B21">21</xref>). Vesicles, carrying oxidative stress signal transmitters, are released in the extra-cellular volume, but are actively transported back into the intra-cellular volume to modulate oxidative stress and fluid imbalance (<xref ref-type="bibr" rid="B50">50</xref>). The near-significant difference in the volume ratio compared to the significant difference in overall and intra-cellular transverse relaxation times might be the result of intrinsic lower effect size compared to measurement error, but might potentially indicate the secondary effects of structural changes (<xref ref-type="bibr" rid="B51">51</xref>) following biochemical alteration (<xref ref-type="bibr" rid="B52">52</xref>). Protective homeostatic mechanism (<xref ref-type="bibr" rid="B49">49</xref>), modulating fluid exchange through vesicles between the compartments (<xref ref-type="bibr" rid="B50">50</xref>), may dampen the effects of proliferative activities on the volume ratio with the same trend but weaker significance against transverse relaxation times (<xref ref-type="bibr" rid="B53">53</xref>).</p>
<p>The negative correlation between extra-cellular transverse relaxation time and tumour diameter might be due to the increased cellularity and reduced extra-cellular free water pools associated with larger tumours (<xref ref-type="bibr" rid="B48">48</xref>). The significant negative correlation between extra-cellular transverse relaxation time and tumour size indicates a more concentrated biochemical environment or less free water at larger tumour size. Larger tumours suffer from hypoxia due to inadequate vascular supply (<xref ref-type="bibr" rid="B54">54</xref>) and extra-cellular matrix remodelling (<xref ref-type="bibr" rid="B55">55</xref>), and the increase in the macromolecules to water ratio in the extra-cellular compartment (<xref ref-type="bibr" rid="B56">56</xref>) lead to a reduction in extra-cellular transverse relaxation time (<xref ref-type="bibr" rid="B57">57</xref>). There was no significant correlation between overall transverse relaxation time, intra-cellular transverse relaxation time and volume ratio with tumour diameter, reflecting the insensitivity of the three relaxometry properties to morphological tumour size. The lack of significant correlation between overall transverse relaxation time, intra-cellular and extra-cellular transverse relaxation times and volume ratio against NPI indicated that the four relaxometry properties, although potential treatment monitoring markers, might not be sensitive to recurrence and metastatic risks revealed by NPI (<xref ref-type="bibr" rid="B58">58</xref>).</p>
<p>Although an understanding of the heterogeneity in the overall and intra-cellular transverse relaxation times required thorough quantitative analysis across the whole tumour using appropriate texture features, however conjectural visual exploration might serve to develop future hypothesis. Intra-cellular transverse relaxation time showed sparse focal elevation at the edges of high proliferating tumours but more homogeneity in low proliferating tumours, while overall transverse relaxation time showed more homogeneous elevation in high proliferating tumours but exhibited bands of elevation at the edges of low proliferating tumours (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>). The focal increase in intra-cellular free water content, manifested as a lengthening of intra-cellular transverse relaxation time, in high proliferating tumours might reflect the elevated transportation of amino acids into the nucleus from the cytoplasmic space to sustain biosynthesis in the nucleus at the advancing edge of the tumour (<xref ref-type="bibr" rid="B44">44</xref>). The bands of increased free water content, manifested as the elevation of overall transverse relaxation time, at the edge of low proliferating tumours might reflect the presence of angiogenesis and oedema concentrated at the tumour margin (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B42">42</xref>), in contrast to their widespread presence across the whole tumour in high proliferating tumours (<xref ref-type="bibr" rid="B24">24</xref>). Precise spatial correlation between imaging and pathology, demanding co-localisation at a fine cellular resolution, was not feasible during this study, and should be performed in future investigations.</p>
<p>To our knowledge, this is the first study investigating the relaxation properties as a marker of breast tumour proliferative activity using Bayesian algorithm in conjunction with multi-compartment model to mitigate the impact from noise. This study only recruited patients with large breast tumours to take into account the reliance of Bayesian algorithm on neighbouring voxels, and necrotic tumour cores were excluded from analysis to avoid confounding factors from non-viable tissue in large tumours. The tumours were freshly excised to eliminate biological noise and further improve analysis accuracy, and imaging was performed immediately to avoid the alteration to relaxation properties from formalin submersion (<xref ref-type="bibr" rid="B59">59</xref>). The cohort size was small due to inclusion criteria on large tumour to accommodate novel imaging methods, and future large cohort studies on patients are critical to fully understand the value of the imaging marker. Future simulation study on the variability and high resolution imaging from ultra-high field MRI can support the establishment of a confidence range in sensitivity and an estimation of the highest effective image resolution, allowing studies to be carried out at a higher image resolution and in smaller tumours.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusions</title>
<p>Overall and Bayesian intra-cellular transverse relaxation times are associated with proliferative activities in breast tumours, potentially serving as a non-invasive imaging marker for neoadjuvant treatment monitoring.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by North-West - Greater Manchester East Research Ethics Committee (REC Reference: 16/NW/0221). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>KAN: Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing, Conceptualization. SMC: Conceptualization, Data curation, Investigation, Methodology, Project administration, Software, Supervision, Validation, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. NS: Data curation, Investigation, Project administration, Writing &#x2013; review &amp; editing. JH: Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Software, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This project was funded by NHS Grampian Endowment Research Fund (15/1/052). KAN&#x2019;s PhD study is supported by the Commonwealth Scholarship Commission UK (ZMCS-2020-870). SMC was funded by Cancer Research UK (C68628/A28312). The funding sources were not involved in the study design, in the collection, analysis and interpretation of data, in the writing of the report nor in the decision to submit the article for publication.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>The authors would like to thank Dr. Matthew Clemence (Philips Healthcare Clinical Science, UK) for clinical scientist support, Ms. Bolanle Brikinns for patient recruitment support and Ms. Dawn Younie for logistic support.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2025.1482112/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2025.1482112/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.pdf" id="SM1" mimetype="application/pdf"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>John</surname> <given-names>S</given-names>
</name>
<name>
<surname>Broggio</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Cancer survival in England adult, stage at diagnosis and childhood - patients followed up to 2018</article-title> (<year>2019</year>). <publisher-name>Office for National Statistics</publisher-name>. Available online at: <uri xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinengland/stageatdiagnosisandchildhoodpatientsfollowedupto2018">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinengland/stageatdiagnosisandchildhoodpatientsfollowedupto2018</uri> (Accessed <access-date>Feb 23, 2024</access-date>).</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="web">
<article-title>Healthcare Quality Indicators: Cancer Care. OECD Data Explorer- Archive</article-title> (<year>2024</year>). Available online at: <uri xlink:href="https://stats.oecd.org/Index.aspx?QueryId=51882">https://stats.oecd.org/Index.aspx?QueryId=51882</uri> (Accessed <access-date>Apr 30, 2024</access-date>).</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferlay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Colombet</surname> <given-names>M</given-names>
</name>
<name>
<surname>Soerjomataram</surname> <given-names>I</given-names>
</name>
<name>
<surname>Parkin</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Pi&#xf1;eros</surname> <given-names>M</given-names>
</name>
<name>
<surname>Znaor</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer statistics for the year 2020: An overview</article-title>. <source>Int J Cancer</source>. (<year>2021</year>) <volume>149</volume>:<page-range>778&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ijc.33588</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asselain</surname> <given-names>B</given-names>
</name>
<name>
<surname>Barlow</surname> <given-names>W</given-names>
</name>
<name>
<surname>Bartlett</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bergh</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bergsten-Nordstr&#xf6;m</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bliss</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials</article-title>. <source>Lancet Oncol</source>. (<year>2018</year>) <volume>19</volume>:<fpage>27</fpage>&#x2013;<lpage>39</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1470-2045(17)30777-5</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baltussen</surname> <given-names>JC</given-names>
</name>
<name>
<surname>de Glas</surname> <given-names>NA</given-names>
</name>
<name>
<surname>van Holstein</surname> <given-names>Y</given-names>
</name>
<name>
<surname>van der Elst</surname> <given-names>M</given-names>
</name>
<name>
<surname>Trompet</surname> <given-names>S</given-names>
</name>
<name>
<surname>Uit den Boogaard</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Chemotherapy-related toxic effects and quality of life and physical functioning in older patients</article-title>. <source>JAMA Netw Open</source>. (<year>2023</year>) <volume>6</volume>:<fpage>e2339116</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.39116</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>National Cancer Institute</collab>
</person-group>. <article-title>Hormone Therapy for Breast Cancer Fact Sheet</article-title> (<year>2022</year>). Available online at: <uri xlink:href="https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheetwhat-are-the-side-effects-of-hormone-therapy">https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheetwhat-are-the-side-effects-of-hormone-therapy</uri> (Accessed <access-date>Feb 26, 2024</access-date>).</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beresford</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>GD</given-names>
</name>
<name>
<surname>Makris</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Measuring proliferation in breast cancer: Practicalities and applications</article-title>. <source>Breast Cancer Res</source>. (<year>2006</year>) <volume>8</volume>(<issue>6</issue>):<fpage>216</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/bcr1618</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilous</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Breast core needle biopsy: issues and controversies</article-title>. <source>Mod Pathol</source>. (<year>2010</year>) <volume>23 Suppl 2</volume>:<page-range>S36&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/modpathol.2010.34</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>YJ</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>YQ</given-names>
</name>
<name>
<surname>Li</surname> <given-names>XR</given-names>
</name>
</person-group>. <article-title>Status quo and development trend of breast biopsy technology</article-title>. <source>Gland Surg</source>. (<year>2013</year>) <volume>2</volume>:<fpage>15</fpage>&#x2013;<lpage>24</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3978/j.issn.2227-684X.2013.02.01</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kenny</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Vigushin</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Al-Nahhas</surname> <given-names>A</given-names>
</name>
<name>
<surname>Osman</surname> <given-names>S</given-names>
</name>
<name>
<surname>Luthra</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Shousha</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods</article-title>. <source>Cancer Res</source>. (<year>2005</year>) <volume>65</volume>:<page-range>10104&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4297</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>EL-Metwally</surname> <given-names>D</given-names>
</name>
<name>
<surname>Monier</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hassan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Helal</surname> <given-names>AM</given-names>
</name>
</person-group>. <article-title>Preoperative prediction of Ki-67 status in invasive breast carcinoma using dynamic contrast-enhanced MRI, diffusion-weighted imaging and diffusion tensor imaging</article-title>. <source>Egyptian J Radiol Nucl Med</source>. (<year>2023</year>) <volume>54</volume>:<fpage>62</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s43055-023-01007-y</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Miao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Differences in tumour heterogeneity based on dynamic contrast-enhanced MRI between tumour and peritumoural stroma for predicting Ki-67 status of invasive ductal carcinoma</article-title>. <source>Clin Radiol</source>. (<year>2021</year>) <volume>76</volume>:<fpage>470.e13</fpage>&#x2013;<lpage>470.e22</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.crad.2020.12.008</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mann</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Kuhl</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Kinkel</surname> <given-names>K</given-names>
</name>
<name>
<surname>Boetes</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Breast MRI: guidelines from the european society of breast imaging</article-title>. <source>Eur Radiol</source>. (<year>2008</year>) <volume>18</volume>:<page-range>1307&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-008-0863-7</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Predicting of ki-67 expression level using diffusion-weighted and synthetic magnetic resonance imaging in invasive ductal breast cancer</article-title>. <source>Breast J</source>. (<year>2023</year>) <volume>2023</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2023/6746326</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fowler</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Mankoff</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Joe</surname> <given-names>BN</given-names>
</name>
</person-group>. <article-title>Imaging neoadjuvant therapy response in breast cancer</article-title>. <source>Radiology</source>. (<year>2017</year>) <volume>285</volume>:<page-range>358&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.2017170180</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Senn</surname> <given-names>N</given-names>
</name>
<name>
<surname>Husain</surname> <given-names>E</given-names>
</name>
<name>
<surname>Masannat</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Heys</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Peri-tumoural spatial distribution of lipid composition and tubule formation in breast cancer</article-title>. <source>BMC Cancer</source>. (<year>2022</year>) <volume>22</volume>:<fpage>285</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12885-022-09362-1</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>WS</given-names>
</name>
<name>
<surname>Senn</surname> <given-names>N</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>R</given-names>
</name>
<name>
<surname>McGoldrick</surname> <given-names>T</given-names>
</name>
<name>
<surname>Gagliardi</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Towards detection of early response in neoadjuvant chemotherapy of breast cancer using Bayesian intravoxel incoherent motion</article-title>. <source>Front Oncol</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1277556</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2023.1277556</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szubert-Franczak</surname> <given-names>AE</given-names>
</name>
<name>
<surname>Naduk-Ostrowska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pasicz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Podg&#xf3;rska</surname> <given-names>J</given-names>
</name>
<name>
<surname>Skrzy&#x144;ski</surname> <given-names>W</given-names>
</name>
<name>
<surname>Cieszanowski</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Intravoxel incoherent motion magnetic resonance imaging: basic principles and clinical applications</article-title>. <source>Pol J Radiol</source>. (<year>2020</year>) <volume>85</volume>:<page-range>624&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5114/pjr.2020.101476</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merchant</surname> <given-names>TE</given-names>
</name>
<name>
<surname>Thelissen</surname> <given-names>GRP</given-names>
</name>
<name>
<surname>de Graaf</surname> <given-names>PW</given-names>
</name>
<name>
<surname>Nieuwenhuizen</surname> <given-names>CWEA</given-names>
</name>
<name>
<surname>Kievit</surname> <given-names>HCE</given-names>
</name>
<name>
<surname>den Otter</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Application of a mixed imaging sequence for MR imaging characterization of human breast disease</article-title>. <source>Acta Radiol</source>. (<year>1993</year>) <volume>34</volume>:<page-range>356&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/02841859309173257</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ababneh</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Beloeil</surname> <given-names>H</given-names>
</name>
<name>
<surname>Berde</surname> <given-names>CB</given-names>
</name>
<name>
<surname>Gambarota</surname> <given-names>G</given-names>
</name>
<name>
<surname>Maier</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Mulkern</surname> <given-names>RV</given-names>
</name>
</person-group>. <article-title>Biexponential parameterization of diffusion and T2 relaxation decay curves in a rat muscle edema model: Decay curve components and water compartments</article-title>. <source>Magn Reson Med</source>. (<year>2005</year>) <volume>54</volume>:<page-range>524&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mrm.20610</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>CB</given-names>
</name>
</person-group>. <article-title>Metabolic regulation of cell growth and proliferation</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2019</year>) <volume>20</volume>:<page-range>436&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41580-019-0123-5</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Generali</surname> <given-names>DG</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>Breast tumour angiogenesis</article-title>. <source>Breast Cancer Res</source>. (<year>2007</year>) <volume>9</volume>:<fpage>216</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/bcr1796</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marques</surname> <given-names>MPM</given-names>
</name>
<name>
<surname>de Carvalho</surname> <given-names>ALMB</given-names>
</name>
<name>
<surname>Martins</surname> <given-names>CB</given-names>
</name>
<name>
<surname>Silva</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Sarter</surname> <given-names>M</given-names>
</name>
<name>
<surname>Garc&#xed;a Sakai</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Cellular dynamics as a marker of normal-to-cancer transition in human cells</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>21079</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-023-47649-w</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuda</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kido</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tsuda</surname> <given-names>T</given-names>
</name>
<name>
<surname>Okada</surname> <given-names>K</given-names>
</name>
<name>
<surname>Shiraishi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Suekuni</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Utility of synthetic MRI in predicting the Ki-67 status of oestrogen receptor-positive breast cancer: a feasibility study</article-title>. <source>Clin Radiol</source>. (<year>2020</year>) <volume>75</volume>:<page-range>398.e1&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.crad.2019.12.021</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>T&#x151;k&#xe9;s</surname> <given-names>T</given-names>
</name>
<name>
<surname>T&#x151;k&#xe9;s</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Szentm&#xe1;rtoni</surname> <given-names>G</given-names>
</name>
<name>
<surname>Kiszner</surname> <given-names>G</given-names>
</name>
<name>
<surname>Madaras</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kulka</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer</article-title>. <source>Virchows Archiv</source>. (<year>2016</year>) <volume>468</volume>:<page-range>675&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00428-016-1925-x</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>M</given-names>
</name>
<name>
<surname>He</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy</article-title>. <source>Prostate</source>. (<year>2021</year>) <volume>81</volume>:<page-range>560&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/pros.24134</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabouri</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Savdie</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>EC</given-names>
</name>
<name>
<surname>Goldenberg</surname> <given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>Luminal water imaging: a new MRI T2 mapping technique for prostate cancer diagnosis</article-title>. <source>Radiology</source>. (<year>2017</year>) <volume>284</volume>:<page-range>451&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.2017161687</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikiforaki</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ioannidis</surname> <given-names>GS</given-names>
</name>
<name>
<surname>Lagoudaki</surname> <given-names>E</given-names>
</name>
<name>
<surname>Manikis</surname> <given-names>GH</given-names>
</name>
<name>
<surname>de Bree</surname> <given-names>E</given-names>
</name>
<name>
<surname>Karantanas</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Multiexponential T2 relaxometry of benign and Malignant adipocytic tumours</article-title>. <source>Eur Radiol Exp</source>. (<year>2020</year>) <volume>4</volume>:<fpage>45</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s41747-020-00175-0</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reiter</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Irrechukwu</surname> <given-names>O</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Moghadam</surname> <given-names>S</given-names>
</name>
<name>
<surname>von Thaer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pleshko</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Improved MR-based characterization of engineered cartilage using multiexponential T2 relaxation and multivariate analysis</article-title>. <source>NMR Biomed</source>. (<year>2012</year>) <volume>25</volume>:<page-range>476&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/nbm.1804</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bj&#xf6;rk</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zachariah</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kullberg</surname> <given-names>J</given-names>
</name>
<name>
<surname>Stoica</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>A multicomponent T2 relaxometry algorithm for myelin water imaging of the brain</article-title>. <source>Magn Reson Med</source>. (<year>2016</year>) <volume>75</volume>:<fpage>390</fpage>&#x2013;<lpage>402</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mrm.25583</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Romanov</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ladutenko</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zubkov</surname> <given-names>M</given-names>
</name>
<name>
<surname>Andreychenko</surname> <given-names>A</given-names>
</name>
</person-group>. (<year>2022</year>). <article-title>Method of moments for relaxation-based signal separation in magnetic resonance breast cancer detection</article-title>, in: <conf-name>2022 IEEE International Multi-Conference on Engineering, Computer and Information Sciences (SIBIRCON)</conf-name>, <conf-loc>Yekaterinburg, Russia</conf-loc>, <conf-date>2022 Nov 11 &#x2013; 13</conf-date>. pp. <page-range>630&#x2013;3</page-range>. <publisher-loc>New Jersey, USA</publisher-loc>: <publisher-name>IEEE</publisher-name>.</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bretthorst</surname> <given-names>GL</given-names>
</name>
<name>
<surname>Hutton</surname> <given-names>WC</given-names>
</name>
<name>
<surname>Garbow</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Ackerman</surname> <given-names>JJH</given-names>
</name>
</person-group>. <article-title>Exponential parameter estimation (in NMR) using bayesian probability theory</article-title>. <source>Concepts Magn Reson Part A</source>. (<year>2005</year>) <volume>27A</volume>:<fpage>55</fpage>&#x2013;<lpage>63</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cmr.a.20043</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouhrara</surname> <given-names>M</given-names>
</name>
<name>
<surname>Reiter</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Spencer</surname> <given-names>RG</given-names>
</name>
</person-group>. <article-title>Bayesian analysis of transverse signal decay with application to human brain</article-title>. <source>Magn Reson Med</source>. (<year>2015</year>) <volume>74</volume>:<fpage>785</fpage>&#x2013;<lpage>802</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mrm.25457</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gustafsson</surname> <given-names>O</given-names>
</name>
<name>
<surname>Montelius</surname> <given-names>M</given-names>
</name>
<name>
<surname>Starck</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ljungberg</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Impact of prior distributions and central tendency measures on Bayesian intravoxel incoherent motion model fitting</article-title>. <source>Magn Reson Med</source>. (<year>2018</year>) <volume>79</volume>:<page-range>1674&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mrm.26783</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elston</surname> <given-names>CW</given-names>
</name>
<name>
<surname>Ellis</surname> <given-names>IO</given-names>
</name>
</person-group>. <article-title>pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up</article-title>. <source>Histopathology</source>. (<year>1991</year>) <volume>19</volume>:<page-range>403&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-2559.1991.tb00229.x</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuominen</surname> <given-names>VJ</given-names>
</name>
<name>
<surname>Ruotoistenm&#xe4;ki</surname> <given-names>S</given-names>
</name>
<name>
<surname>Viitanen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jumppanen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Isola</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67</article-title>. <source>Breast Cancer Res</source>. (<year>2010</year>) <volume>12</volume>:<fpage>R56</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/bcr2615</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldhirsch</surname> <given-names>A</given-names>
</name>
<name>
<surname>Winer</surname> <given-names>EP</given-names>
</name>
<name>
<surname>Coates</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Gelber</surname> <given-names>RD</given-names>
</name>
<name>
<surname>Piccart-Gebhart</surname> <given-names>M</given-names>
</name>
<name>
<surname>Th&#xfc;rlimann</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013</article-title>. <source>Ann Oncol</source>. (<year>2013</year>) <volume>24</volume>:<page-range>2206&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/annonc/mdt303</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yerushalmi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Woods</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ravdin</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Hayes</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Gelmon</surname> <given-names>KA</given-names>
</name>
</person-group>. <article-title>Ki67 in breast cancer: prognostic and predictive potential</article-title>. <source>Lancet Oncol</source>. (<year>2010</year>) <volume>11</volume>:<page-range>174&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1470-2045(09)70262-1</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denkert</surname> <given-names>C</given-names>
</name>
<name>
<surname>Loibl</surname> <given-names>S</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Eidtmann</surname> <given-names>H</given-names>
</name>
<name>
<surname>Schmitt</surname> <given-names>WD</given-names>
</name>
<name>
<surname>Eiermann</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial</article-title>. <source>Ann Oncol</source>. (<year>2013</year>) <volume>24</volume>:<fpage>2786</fpage>&#x2013;<lpage>2793</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/annonc/mdt350</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Chien</surname> <given-names>CP</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>WC</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>HW</given-names>
</name>
</person-group>. <article-title>Gradient- and spin-echo (GRASE) MR imaging: a long-existing technology that may find wide applications in modern era</article-title>. <source>Quant Imaging Med Surg</source>. (<year>2019</year>) <volume>9</volume>:<page-range>1477&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/qims.2019.09.13</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amano</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fujita</surname> <given-names>S</given-names>
</name>
<name>
<surname>Takei</surname> <given-names>N</given-names>
</name>
<name>
<surname>Sano</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wada</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Feasibility of quantitative MRI using 3D-QALAS for discriminating immunohistochemical status in invasive ductal carcinoma of the breast</article-title>. <source>J Magnetic Resonance Imaging</source>. (<year>2023</year>) <volume>58</volume>:<page-range>1752&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmri.28683</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ould Ismail</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Wolf</surname> <given-names>R</given-names>
</name>
<name>
<surname>Brem</surname> <given-names>S</given-names>
</name>
<name>
<surname>Alexander</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hodges</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Freewater estimatoR using iNtErpolated iniTialization (FERNET): Characterizing peritumoral edema using clinically feasible diffusion MRI data</article-title>. <source>PloS One</source>. (<year>2020</year>) <volume>15</volume>:<fpage>e0233645</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0233645</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilatus</surname> <given-names>U</given-names>
</name>
<name>
<surname>Shim</surname> <given-names>H</given-names>
</name>
<name>
<surname>Artemov</surname> <given-names>D</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>D</given-names>
</name>
<name>
<surname>Van Zijl</surname> <given-names>PCM</given-names>
</name>
<name>
<surname>Glickson</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>Intracellular volume and apparent diffusion constants of perfused cancer cell cultures, as measured by NMR</article-title>. <source>Magn Reson Med</source>. (<year>1997</year>) <volume>37</volume>:<page-range>825&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mrm.1910370605</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palm</surname> <given-names>W</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>CB</given-names>
</name>
</person-group>. <article-title>Nutrient acquisition strategies of mammalian cells</article-title>. <source>Nature</source>. (<year>2017</year>) <volume>546</volume>:<page-range>234&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature22379</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Song</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Tumor microenvironment-activated theranostic nanoreactor for NIR-II Photoacoustic imaging-guided tumor-specific photothermal therapy</article-title>. <source>Fundam Res</source>. (<year>2024</year>) <volume>4</volume>:<page-range>178&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.fmre.2022.04.021</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uchiyama</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>QL</given-names>
</name>
<name>
<surname>Hassan</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Andocs</surname> <given-names>G</given-names>
</name>
<name>
<surname>Nojima</surname> <given-names>N</given-names>
</name>
<name>
<surname>Takeda</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>EPR-spin trapping and flow cytometric studies of free radicals generated using cold atmospheric argon plasma and X-ray irradiation in aqueous solutions and intracellular milieu</article-title>. <source>PloS One</source>. (<year>2015</year>) <volume>10</volume>:<fpage>e0136956</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0136956</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morry</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ngamcherdtrakul</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yantasee</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles</article-title>. <source>Redox Biol</source>. (<year>2017</year>) <volume>11</volume>:<fpage>240</fpage>&#x2013;<lpage>253</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2016.12.011</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dewhirst</surname> <given-names>MW</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Moeller</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response</article-title>. <source>Nat Rev Cancer</source>. (<year>2008</year>) <volume>8</volume>:<page-range>425&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrc2397</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morishita</surname> <given-names>K</given-names>
</name>
<name>
<surname>Watanabe</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ichijo</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Cell volume regulation in cancer cell migration driven by osmotic water flow</article-title>. <source>Cancer Sci</source>. (<year>2019</year>) <volume>110</volume>:<page-range>2337&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cas.14079</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dorado</surname> <given-names>E</given-names>
</name>
<name>
<surname>Doria</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Nagelkerke</surname> <given-names>A</given-names>
</name>
<name>
<surname>McKenzie</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Maneta-Stavrakaki</surname> <given-names>S</given-names>
</name>
<name>
<surname>Whittaker</surname> <given-names>TE</given-names>
</name>
<etal/>
</person-group>. <article-title>Extracellular vesicles as a promising source of lipid biomarkers for breast cancer detection in blood plasma</article-title>. <source>J Extracell Vesicles</source>. (<year>2024</year>) <volume>13</volume>:<fpage>e12419</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jev2.12419</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youk</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Son</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>Ek</given-names>
</name>
</person-group>. <article-title>Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes</article-title>. <source>Eur Radiol</source>. (<year>2012</year>) <volume>22</volume>:<page-range>1724&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-012-2425-2</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akg&#xfc;l</surname> <given-names>S</given-names>
</name>
<name>
<surname>Patch</surname> <given-names>AM</given-names>
</name>
<name>
<surname>D&#x2019;souza</surname> <given-names>RCJ</given-names>
</name>
<name>
<surname>Mukhopadhyay</surname> <given-names>P</given-names>
</name>
<name>
<surname>Nones</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kempe</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Intratumoural heterogeneity underlies distinct therapy responses and treatment resistance in glioblastoma</article-title>. <source>Cancers</source>. (<year>2019</year>) <volume>11</volume>:<elocation-id>190</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/CANCERS11020190</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pegoraro</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>EH</given-names>
</name>
<name>
<surname>Arany</surname> <given-names>PR</given-names>
</name>
<name>
<surname>Han</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Cell volume change through water efflux impacts cell stiffness and stem cell fate</article-title>. <source>PNAS</source>. (<year>2017</year>) <volume>114</volume>(<issue>41</issue>): <page-range>E8618&#x2013;E8627</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1705179114</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ser&#x161;a</surname> <given-names>I</given-names>
</name>
<name>
<surname>Bajd</surname> <given-names>F</given-names>
</name>
<name>
<surname>Savarin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jesenko</surname> <given-names>T</given-names>
</name>
<name>
<surname>&#x10c;ema&#x17e;ar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ser&#x161;a</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Multiparametric high-resolution MRI as a tool for mapping of hypoxic level in tumors</article-title>. <source>Technol Cancer Res Treat</source>. (<year>2018</year>) <volume>17</volume>:<page-range>1&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/1533033818797066</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Extracellular matrix characterization in gastric cancer helps to predict prognosis and chemotherapy response</article-title>. <source>Front Oncol</source>. (<year>2021</year>) <volume>11</volume>:<elocation-id>753330</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2021.753330</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drain</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Zahir</surname> <given-names>N</given-names>
</name>
<name>
<surname>Northey</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Maller</surname> <given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Matrix compliance permits NF-&#x3ba;B activation to drive therapy resistance in breast cancer</article-title>. <source>J Exp Med</source>. (<year>2021</year>) <volume>218</volume>(<issue>5</issue>):<elocation-id>e20191360</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20191360</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Souza</surname> <given-names>FF</given-names>
</name>
<name>
<surname>D&#x2019;Amato</surname> <given-names>G</given-names>
</name>
<name>
<surname>Jonczak</surname> <given-names>EE</given-names>
</name>
<name>
<surname>Costa</surname> <given-names>P</given-names>
</name>
<name>
<surname>Trent</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Rosenberg</surname> <given-names>AE</given-names>
</name>
<etal/>
</person-group>. <article-title>MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results</article-title>. <source>Front Oncol</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1286807</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2023.1286807</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="web">
<article-title>Diagnostics Advisory committee members and NICE project team. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer Diagnostics guidance</article-title> (<year>2024</year>). <publisher-name>NICE guidance</publisher-name>. Available online at: <uri xlink:href="http://www.nice.org.uk/guidance/dg58">www.nice.org.uk/guidance/dg58</uri> (Accessed <access-date>Aug 15, 2024</access-date>).</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebata</surname> <given-names>K</given-names>
</name>
<name>
<surname>Noriki</surname> <given-names>S</given-names>
</name>
<name>
<surname>Inai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kimura</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Changes in magnetic resonance imaging relaxation time on postmortem magnetic resonance imaging of formalin-fixed human normal heart tissue</article-title>. <source>BMC Med Imaging</source>. (<year>2021</year>) <volume>21</volume>:<fpage>134</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12880-021-00666-5</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>